This offers new hope to tens of millions of sufferers of neurodegenerative diseases and the start-up also has the study entered in its Phase 1 clinical trials.
The Breakthrough Drug
The innovative drug candidate NVG-291 is a small protein (a peptide) that targets the protein tyrosine phosphatase sigma (PTPσ) receptor. This receptor is responsible for blocking the nerve repair following injury (trauma or degenerative conditions).
NervGen designed the drug to target nerve cell repair, and simultaneously also promote plasticity for creating new neural pathways. The study team is currently conducting the trials in healthy volunteers that would follow its transition to studies for several medical ailments.
The company affirms its interest in NVG-291’s ability to tackle Alzheimer’s disease. After the ongoing Phase 1 safety trials for the drug candidate, it is also prepared to enter a Phase 1b clinical trial for Alzheimer’s patients in 2022.
“What differentiates NVG-291 from other drugs in development is that it leverages multiple mechanisms for repairing nerve damage, while most others focus on a single approach. Alzheimer’s disease is a complex condition and likely caused by multiple factors. We believe that a systems approach to treating the disease is an important distinction. NVG-291’s ability to remyelinate and enhance plasticity is a one-two knockout punch for repairing a faulty central nervous system, which is the end result on a diversity of neurodegenerative diseases, as well as traumatic brain and spinal injuries,” says NervGen’s CEO, Paul Brennan.
Source: Medindia
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
